pI: 6.0373 |
Length (AA): 457 |
MW (Da): 50658 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 10 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
2 | 71 | 2gbr (A) | 1 | 75 | 24.00 | 0 | 1 | 0.52 | -1.62 |
2 | 79 | 1v5t (A) | 8 | 88 | 36.00 | 0 | 1 | 0.64 | -0.82 |
96 | 445 | 2gfo (A) | 769 | 1108 | 27.00 | 0.000000000038 | 1 | 0.72 | 0 |
100 | 443 | 2ayn (A) | 100 | 479 | 31.00 | 0 | 1 | 1.08 | -0.25 |
101 | 447 | 1vjv (A) | 106 | 498 | 26.00 | 0 | 1 | 1.03 | -0.79 |
1 | 76 | 1v5t (A) | 7 | 85 | 38.00 | 0 | 1 | 0.623802 | -0.41 |
2 | 45 | 2kan (A) | 16 | 59 | 25.00 | 0.013 | 0.84 | 0.52188 | -1.14 |
3 | 71 | 3phx (B) | 83 | 151 | 28.00 | 0 | 1 | 0.637485 | -1.6 |
105 | 446 | 2ayn (A) | 105 | 482 | 35.00 | 0 | 1 | 1.09016 | -0.1 |
105 | 456 | 1nbf (A) | 215 | 538 | 20.00 | 0 | 1 | 0.709741 | 0.46 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | amastigotes. | Fernandes MC |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | metacyclic. | Fernandes MC |
Fernandes MC | Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures. |
Ortholog group members (OG5_127806)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT1G51710 | ubiquitin carboxyl-terminal hydrolase 6 |
Arabidopsis thaliana | AT3G21280 | ubiquitin-specific protease 7 |
Babesia bovis | BBOV_III008630 | ubiquitin carboxyl-terminal hydrolase family protein |
Brugia malayi | Bm1_28765 | ubiquitin specific protease 14 |
Brugia malayi | Bm1_56885 | Ubiquitin carboxyl-terminal hydrolase family protein |
Brugia malayi | Bm1_28760 | hypothetical protein |
Candida albicans | CaO19.6063 | ubiquitin-specific protease |
Candida albicans | CaO19.13484 | ubiquitin-specific protease |
Caenorhabditis elegans | CELE_C13B4.2 | Protein USP-14 |
Cryptosporidium hominis | Chro.10040 | tRNA-guaninine transglycosylase |
Cryptosporidium parvum | cgd1_290 | Ub6p like ubiquitin at N-terminus and ubiquitin C terminal hydrolase at the C-terminus |
Dictyostelium discoideum | DDB_G0271264 | peptidase C19 family protein |
Drosophila melanogaster | Dmel_CG5384 | CG5384 gene product from transcript CG5384-RB |
Echinococcus granulosus | EgrG_000580300 | ubiquitin carboxyl terminal hydrolase 14 |
Echinococcus multilocularis | EmuJ_000580300 | ubiquitin carboxyl terminal hydrolase 14 |
Giardia lamblia | GL50803_8189 | Ubiquitin carboxyl-terminal hydrolase 14 |
Homo sapiens | 9097 | ubiquitin specific peptidase 14 (tRNA-guanine transglycosylase) |
Leishmania braziliensis | LbrM.31.0140 | ubiquitin hydrolase, putative,cysteine peptidase, Clan CA, family C19, putative |
Leishmania donovani | LdBPK_310150.1 | ubiquitin carboxyl-terminal hydrolase, putative |
Leishmania infantum | LinJ.31.0150 | ubiquitin hydrolase, putative,cysteine peptidase, Clan CA, family C19, putative |
Leishmania major | LmjF.31.0140 | ubiquitin hydrolase, putative,cysteine peptidase, Clan CA, family C19, putative |
Leishmania mexicana | LmxM.30.0140 | ubiquitin hydrolase, putative,cysteine peptidase, Clan CA, family C19, putative |
Loa Loa (eye worm) | LOAG_02396 | hypothetical protein |
Loa Loa (eye worm) | LOAG_02397 | hypothetical protein |
Mus musculus | ENSMUSG00000047879 | ubiquitin specific peptidase 14 |
Neospora caninum | NCLIV_055070 | Ubiquitin carboxyl-terminal hydrolase (EC 3.1.2.15), related |
Oryza sativa | 4326194 | Os01g0550100 |
Plasmodium berghei | PBANKA_1242000 | ubiquitin carboxyl-terminal hydrolase 14, putative |
Plasmodium falciparum | PF3D7_0527200 | ubiquitin carboxyl-terminal hydrolase 14 |
Plasmodium knowlesi | PKNH_1005500 | ubiquitin carboxyl-terminal hydrolase 14, putative |
Plasmodium vivax | PVX_079880 | ubiquitin carboxyl-terminal hydrolase, putative |
Plasmodium yoelii | PY03738 | tRNA-guaninine transglycosylase, putative, putative |
Saccharomyces cerevisiae | YFR010W | Ubp6p |
Schistosoma japonicum | Sjp_0209980 | ko:K01072 ubiquitin thiolesterase [EC3.1.2.15], putative |
Schistosoma japonicum | Sjp_0209970 | ko:K01072 ubiquitin thiolesterase [EC3.1.2.15], putative |
Schistosoma mansoni | Smp_084740 | ubiquitin-specific peptidase 14 (C19 family) |
Schmidtea mediterranea | mk4.009566.00 | Ubiquitin carboxyl-terminal hydrolase 14 |
Trypanosoma brucei gambiense | Tbg972.4.3850 | ubiquitin carboxyl-terminal hydrolase, putative,cysteine peptidase, Clan CA, family C19, putative |
Trypanosoma brucei | Tb927.4.3790 | ubiquitin carboxyl-terminal hydrolase, putative |
Trypanosoma congolense | TcIL3000_0_29070 | ubiquitin carboxyl-terminal hydrolase, putative |
Trypanosoma congolense | TcIL3000_4_3320 | ubiquitin carboxyl-terminal hydrolase, putative |
Trypanosoma congolense | TcIL3000_0_32960 | ubiquitin carboxyl-terminal hydrolase, putative |
Trypanosoma cruzi | TcCLB.504443.10 | ubiquitin carboxyl-terminal hydrolase, putative |
Trypanosoma cruzi | TcCLB.506569.10 | ubiquitin carboxyl-terminal hydrolase, putative |
Toxoplasma gondii | TGME49_311090 | ubiquitin carboxyl-terminal hydrolase |
Theileria parva | TP04_0767 | ubiquitin carboxyl-terminal hydrolase, putative |
Trichomonas vaginalis | TVAG_296140 | Clan CA, family C19, ubiquitin hydrolase-like cysteine peptidase |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.4.3790 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.4.3790 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.4.3790 | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb927.4.3790 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
PBANKA_1242000 | Plasmodium berghei | Dispensable | plasmo |
TGME49_311090 | Toxoplasma gondii | Essentiality uncertain | sidik |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | inferred from bioassay (ECO:0000094) | Leishmania mexicana | 337527 561727 585910 |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 4174-73-6. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in cell assay; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 7179420 | |
growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania mexicana | 337527 561727 585910 |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 4174-73-6. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in cell assay; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 7179420 | |
catalytic activity (GO:0003824) | decreased (PATO:0000468) | in vitro (MI:0492) | inferred from enzyme assay (ECO:0000005) | Leishmania mexicana | 337527 561727 585910 | |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 4174-73-6. chemical inhibition with known cysteine peptidase inhibitors leads to reduced enzyme activity in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 7179420 | |
growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | inferred from bioassay (ECO:0000094) | Leishmania amazonensis | No drug identifiers listed for this gene. |
Annotator: | aaronjr@u.washington.edu. | Comment: | L-Amino acid esters appear to be hydrolyzed by cysteine peptidase and lead to slow growth of Leishmania sp. in cell assay; . | References: | 1428504 2235078 2345655 | |
growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | inferred from bioassay (ECO:0000094) | Leishmania mexicana | No drug identifiers listed for this gene. |
Annotator: | aaronjr@u.washington.edu. | Comment: | chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in cell assay; . | References: | 2270108 | |
catalytic activity (GO:0003824) | decreased (PATO:0000468) | in vitro (MI:0492) | inferred from enzyme assay (ECO:0000005) | Leishmania amazonensis | 81384 576750 | |
Annotator: | aaronjr@u.washington.edu. | Comment: | chemical inhibition with known cysteine peptidase inhibitors leads to reduced enzyme activity in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 8023752 | |
catalytic activity (GO:0003824) | decreased (PATO:0000468) | in vitro (MI:0492) | inferred from enzyme assay (ECO:0000005) | Leishmania major | 81384 576750 | |
Annotator: | aaronjr@u.washington.edu. | Comment: | chemical inhibition with known cysteine peptidase inhibitors leads to reduced enzyme activity in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 8023752 | |
growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | host (GO:0018995) | Leishmania donovani | No drug identifiers listed for this gene. |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 81989-95-9. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in vivo (balb/c mouse) and cure of parasite burden; also provided protection against further infection (partial vaccine); General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 11238649 | |
growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | inferred from bioassay (ECO:0000094) | Leishmania donovani | No drug identifiers listed for this gene. |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 81989-95-9. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in vivo (balb/c mouse) and cure of parasite burden; also provided protection against further infection (partial vaccine); General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 11238649 | |
growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | host (GO:0018995) | Leishmania tropica | No drug identifiers listed for this gene. |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 233277-99-1. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in vivo (balb/c mouse lesions) and reduced lesion size; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 15172223 | |
growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | inferred from bioassay (ECO:0000094) | Leishmania tropica | No drug identifiers listed for this gene. |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 233277-99-1. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in vivo (balb/c mouse lesions) and reduced lesion size; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 15172223 | |
growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania tropica | No drug identifiers listed for this gene. |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 233277-99-1. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in cell assay; inhibitors overcome redundancy?; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 15172223 | |
growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania donovani | 0 6693 81384 236103 327961 376038 543486 543487 575389 575390 575391 576750 |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 22386-37-4; Drug: 36677-78-8; Drug: 52090-11-6; Drug: 98319-30-3; Drug: 300670-24-0; Drug: 302939-54-4; Drug: 303216-44-6; Drug: 309742-24-3; Drug: 312280-89-0; Drug: 315703-20-9; Drug: 320369-30-0; Drug: 322409-94-9; Drug: 330220-86-5; Drug: 335206-77-4; Drug: 347910-28-5; Drug: 352560-86-2; Drug: 363180-61-4; Drug: 413580-11-7; Drug: 416878-80-3; Drug: 419547-26-5; Drug: 428852-79-3; Drug: 825612-08-6; Drug: 825612-09-7; Drug: 825612-10-0. in silico virtual screening of falcipains lead to bioactive compounds against Leishmania promastigotes; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 15588096 | |
catalytic activity (GO:0003824) | decreased (PATO:0000468) | in vitro (MI:0492) | inferred from in-silico analysis (ECO:0000043) | Leishmania donovani | 0 6693 81384 236103 327961 376038 543486 543487 575389 575390 575391 576750 | |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 22386-37-4; Drug: 36677-78-8; Drug: 52090-11-6; Drug: 98319-30-3; Drug: 300670-24-0; Drug: 302939-54-4; Drug: 303216-44-6; Drug: 309742-24-3; Drug: 312280-89-0; Drug: 315703-20-9; Drug: 320369-30-0; Drug: 322409-94-9; Drug: 330220-86-5; Drug: 335206-77-4; Drug: 347910-28-5; Drug: 352560-86-2; Drug: 363180-61-4; Drug: 413580-11-7; Drug: 416878-80-3; Drug: 419547-26-5; Drug: 428852-79-3; Drug: 825612-08-6; Drug: 825612-09-7; Drug: 825612-10-0. in silico virtual screening of falcipains lead to bioactive compounds against cysteine protease in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 15588096 | |
catalytic activity (GO:0003824) | decreased (PATO:0000468) | in vitro (MI:0492) | inferred from specific protein inhibition (ECO:0000020) | Leishmania donovani | 0 6693 81384 236103 327961 376038 543486 543487 575389 575390 575391 576750 | |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 22386-37-4; Drug: 36677-78-8; Drug: 52090-11-6; Drug: 98319-30-3; Drug: 300670-24-0; Drug: 302939-54-4; Drug: 303216-44-6; Drug: 309742-24-3; Drug: 312280-89-0; Drug: 315703-20-9; Drug: 320369-30-0; Drug: 322409-94-9; Drug: 330220-86-5; Drug: 335206-77-4; Drug: 347910-28-5; Drug: 352560-86-2; Drug: 363180-61-4; Drug: 413580-11-7; Drug: 416878-80-3; Drug: 419547-26-5; Drug: 428852-79-3; Drug: 825612-08-6; Drug: 825612-09-7; Drug: 825612-10-0. in silico virtual screening of falcipains lead to bioactive compounds against cysteine protease in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 15588096 | |
growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania donovani | No drug identifiers listed for this gene. |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 2935-91-3; Drug: 24117-97-3; Drug: 98647-23-5; Drug: 198124-18-4; Drug: 256238-87-6; Drug: 257287-52-8; Drug: 263157-80-8; Drug: 294854-43-6; Drug: 303124-84-7; Drug: 303147-38-8; Drug: 321579-84-4; Drug: 331247-87-1; Drug: 337923-53-2; Drug: 338791-39-2; Drug: 675828-74-7; Drug: 676226-56-5; Drug: 678967-57-2; Drug: 681213-40-1; Drug: 686272-33-3; Drug: 696586-43-3; Drug: 705250-31-3; Drug: 708987-83-1; Drug: 831234-40-3; Drug: 882161-95-7; Drug: 882161-98-0; Drug: 882161-99-1; Drug: 882162-00-7; Drug: 882162-01-8; Drug: 882162-02-9; Drug: 882162-03-0; Drug: 882162-04-1; Drug: 882162-05-2; Drug: 882162-06-3; Drug: 882162-07-4; Drug: 882162-08-5; Drug: 882162-09-6; Drug: 882162-10-9; Drug: 882162-11-0; Drug: 882162-12-1; Drug: 882162-13-2; Drug: 882162-14-3. in silico virtual screening of falcipains lead to bioactive compounds against Leishmania promastigotes; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 16509575 | |
catalytic activity (GO:0003824) | decreased (PATO:0000468) | in vitro (MI:0492) | inferred from in-silico analysis (ECO:0000043) | Leishmania donovani | No drug identifiers listed for this gene. | |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 2935-91-3; Drug: 24117-97-3; Drug: 98647-23-5; Drug: 198124-18-4; Drug: 256238-87-6; Drug: 257287-52-8; Drug: 263157-80-8; Drug: 294854-43-6; Drug: 303124-84-7; Drug: 303147-38-8; Drug: 321579-84-4; Drug: 331247-87-1; Drug: 337923-53-2; Drug: 338791-39-2; Drug: 675828-74-7; Drug: 676226-56-5; Drug: 678967-57-2; Drug: 681213-40-1; Drug: 686272-33-3; Drug: 696586-43-3; Drug: 705250-31-3; Drug: 708987-83-1; Drug: 831234-40-3; Drug: 882161-95-7; Drug: 882161-98-0; Drug: 882161-99-1; Drug: 882162-00-7; Drug: 882162-01-8; Drug: 882162-02-9; Drug: 882162-03-0; Drug: 882162-04-1; Drug: 882162-05-2; Drug: 882162-06-3; Drug: 882162-07-4; Drug: 882162-08-5; Drug: 882162-09-6; Drug: 882162-10-9; Drug: 882162-11-0; Drug: 882162-12-1; Drug: 882162-13-2; Drug: 882162-14-3. in silico virtual screening of falcipains lead to bioactive compounds against cysteine protease in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 16509575 | |
catalytic activity (GO:0003824) | decreased (PATO:0000468) | in vitro (MI:0492) | inferred from specific protein inhibition (ECO:0000020) | Leishmania donovani | No drug identifiers listed for this gene. | |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 2935-91-3; Drug: 24117-97-3; Drug: 98647-23-5; Drug: 198124-18-4; Drug: 256238-87-6; Drug: 257287-52-8; Drug: 263157-80-8; Drug: 294854-43-6; Drug: 303124-84-7; Drug: 303147-38-8; Drug: 321579-84-4; Drug: 331247-87-1; Drug: 337923-53-2; Drug: 338791-39-2; Drug: 675828-74-7; Drug: 676226-56-5; Drug: 678967-57-2; Drug: 681213-40-1; Drug: 686272-33-3; Drug: 696586-43-3; Drug: 705250-31-3; Drug: 708987-83-1; Drug: 831234-40-3; Drug: 882161-95-7; Drug: 882161-98-0; Drug: 882161-99-1; Drug: 882162-00-7; Drug: 882162-01-8; Drug: 882162-02-9; Drug: 882162-03-0; Drug: 882162-04-1; Drug: 882162-05-2; Drug: 882162-06-3; Drug: 882162-07-4; Drug: 882162-08-5; Drug: 882162-09-6; Drug: 882162-10-9; Drug: 882162-11-0; Drug: 882162-12-1; Drug: 882162-13-2; Drug: 882162-14-3. in silico virtual screening of falcipains lead to bioactive compounds against cysteine protease in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 16509575 | |
growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania major | No drug identifiers listed for this gene. |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 872361-01-8; Drug: 872361-02-9; Drug: 886061-72-9; Drug: 886061-73-0; Drug: 886061-74-1; Drug: 886061-75-2; Drug: 886061-76-3; Drug: 886061-77-4; Drug: 886061-78-5; Drug: 886061-79-6; Drug: 886061-80-9; Drug: 886061-81-0; Drug: 886061-82-1; Drug: 886061-85-4; Drug: 886061-86-5; Drug: 886061-87-6; Drug: 886061-88-7; Drug: 886061-89-8; Drug: 886061-90-1; Drug: 886061-91-2; Drug: 886061-92-3; Drug: 886061-93-4; Drug: 886061-99-0; Drug: 886062-00-6; Drug: 886062-05-1; Drug: 886062-06-2; Drug: 886062-07-3; Drug: 886062-08-4; Drug: 886062-09-5; Drug: 886062-10-8; Drug: 886062-11-9; Drug: 886062-12-0; Drug: 886062-13-1; Drug: 886062-14-2; Drug: 886062-15-3; Drug: 886062-16-4; Drug: 886062-17-5; Drug: 906674-95-1. chemical inhibition with peptidomimetics and Aziridine-2,3-dicarboxylates leads to slow growth of Leishmania sp. in cell assay; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. | References: | 16801424 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Compound | Source | Reference |
---|---|---|
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References |
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Homo sapiens | ubiquitin specific peptidase 14 (tRNA-guanine transglycosylase) | Compounds | References |
11 literature references were collected for this gene.